Monoclonal antibodies for brain tumour treatment

By Boskovitz Abraham   Wikstrand Carol J   Kuan Chien-Tsun   Zalutsky Michael R   Reardon David A   Bigner Darell D  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 9, 2004-09 ,pp. : 1453-1471

Informa Healthcare

Access to resources Recommend Favorite

Antitumour necrosis factor therapy in Crohn’s disease

By Kaser Arthur   Tilg Herbert  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 7, 2002-10 ,pp. : 715-721

Informa Healthcare

Access to resources Recommend Favorite

Tumour Necrosis Factor alpha Causes Retention of Activated Glucocorticoid Receptor within the Cytoplasm of A549 Cells

By Adcock I.M.   Brown C.R.   Barnes P.J.  

Biochemical and Biophysical Research Communications, Vol. 225, Iss. 2, 1996-08 ,pp. : 545-550

Elsevier

Access to resources Recommend Favorite

Macrophage Metalloelastase Degrades Matrix and Myelin Proteins and Processes a Tumour Necrosis Factor-alpha Fusion Protein

By Chandler S.   Cossins J.   Lury J.   Wells G.  

Biochemical and Biophysical Research Communications, Vol. 228, Iss. 2, 1996-11 ,pp. : 421-429

Elsevier

Access to resources Recommend Favorite

Association of a single nucleotide variant in the human tumour necrosis factor alpha promoter region with decreased bone mineral density

By Ota N.   Nakajima T.   Ezura Y.   Iwasaki H.   Suzuki T.   Hosoi T.   Orimo H.   Inoue S.   Ito H.   Emi M.  

Annals of Human Biology, Vol. 29, Iss. 5, 2002-09 ,pp. : 550-558

Informa Healthcare

Access to resources Recommend Favorite